Liquid biopsy to provide a mutational snapshot of diffuse large B‐cell lymphoma is an emerging technology of exciting potential utility. The report by Alcoceba et al. assesses the tractability of the EuroClonality‐NDC assay to profile lymphoma using cell‐free DNA and highlights the prognostic implication of attaining a major molecular response to therapy. Commentary on: Alcoceba et al. Liquid biopsy for molecular characterization of diffuse large B‐cell lymphoma and early assessment of minimal residual disease. Br J Haematol 2024;205:109–121.
No takes yet. Share an insight, caveat, or question.
Shortt et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: